AKT1 and breast cancer: It is reported that hyperactivation of the phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway is implicated in the tumor genesis of ER+ breast cancer and in resistance to endocrine therapy [34].